NASDAQ:VAXX Vaxxinity (VAXX) Stock Price, News & Analysis $0.03 +0.03 (+∞) (As of 09/6/2024 ET) Add Compare Share Share Today's Range$0.03▼$0.0450-Day Range$0.00▼$0.4052-Week Range$0.00▼$1.87Volume267 shsAverage Volume987,724 shsMarket Capitalization$3.80 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrends Get Vaxxinity alerts: Email Address Ad Paradigm Press Fmr CIA Advisor reveals PEACEMAKER superweaponKamala cannot get the “codes” to this superweapon. In Trump’s hands, it will restore America’s global dominance. It could also help Americans struggling under Bidenomics by potentially sending 5 military stocks SOARING. Historically, similar stocks have shot up 16,270% in just 18 months.Full details are in this announcement. About Vaxxinity Stock (NASDAQ:VAXX)Vaxxinity, Inc., a biotechnology company, focuses on developing product candidates for human use in the fields of neurology, cardiovascular diseases, and coronaviruses in the United States. Its product pipeline comprises UB-311, which is in phase 2 clinical trial that targets toxic forms of aggregated amyloid-b in the brain to fight alzheimer's disease; UB-312, which is in phase 1 clinical trial that targets toxic forms of aggregated a-synuclein in the brain to fight parkinson's disease and other synucleinopathies, such as Lewy body dementia and multiple system atrophy; and VXX-301, which is in preclinical trial, an anti-tau product candidate for various neurodegenerative conditions, including alzheimer's disease, traumatic brain injury, and chronic traumatic encephalopathy. It also develops VXX-401, which is phase 1 clinical trial that targets proprotein convertase subtilisin/kexin type 9 serine protease to lower low-density lipoprotein cholesterol and reduce the risk of cardiac events; UB-313 that targets calcitonin gene-related peptide to fight migraines; and UB-612, neutralizes the SARS-CoV-2 virus and is in phase 3 clinical trial. The company was incorporated in 2021 and is headquartered in Merritt Island, Florida.Read More VAXX Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart VAXX Stock News HeadlinesJune 20, 2024 | globenewswire.comVaxxinity UB-312 Parkinson's Trial Results Published in Nature MedicineMay 3, 2024 | investorplace.comWhy Is Vaxxinity (VAXX) Stock Up 39% Today?September 7, 2024 | Behind the Markets (Ad)NASDAQ to crash 50%?During the 2020 Covid Crash he called a market reversal - eleven days before the S&P bottomed out... Now, he's saying there are four major cracks forming in the US economy...April 22, 2024 | investorplace.comWhy Is Vaxxinity (VAXX) Stock Down 58% Today?April 19, 2024 | marketwatch.comVaxxinity Plans to Delist Shares From NasdaqApril 19, 2024 | globenewswire.comVaxxinity Issues Shareholder LetterApril 19, 2024 | globenewswire.comVaxxinity Announces Intention to Voluntarily Delist and Deregister its Class A Common StockMarch 28, 2024 | globenewswire.comVaxxinity to Present Clinical Data at the Annual Academy of Neurology 2024 Annual MeetingSeptember 7, 2024 | Behind the Markets (Ad)NASDAQ to crash 50%?During the 2020 Covid Crash he called a market reversal - eleven days before the S&P bottomed out... Now, he's saying there are four major cracks forming in the US economy...March 27, 2024 | investorplace.comVAXX Stock Earnings: Vaxxinity Beats EPS for Q4 2023March 27, 2024 | globenewswire.comVaxxinity Reports Fourth Quarter and Full-Year 2023 Financial Results and Provides Corporate UpdatesMarch 7, 2024 | globenewswire.comVaxxinity Announces Positive Target Engagement Data from Phase 1 Clinical Trial for Parkinson's Disease at AD/PD™ 2024February 15, 2024 | finance.yahoo.comVaxxinity’s Heart Health Innovation to Reduce LDL Cholesterol LevelsFebruary 15, 2024 | finance.yahoo.comVaxxinity’s Cholesterol Vaccine Candidate Successfully Lowers LDL-C: Preclinical Data PublishedFebruary 15, 2024 | globenewswire.comVaxxinity's Cholesterol Vaccine Candidate Successfully Lowers LDL-C: Preclinical Data PublishedFebruary 13, 2024 | finance.yahoo.comVaxxinity to Present Clinical and Preclinical Pipeline Data at AD/PD 2024January 30, 2024 | finance.yahoo.comVaxxinity, UF Join Forces Against Neurodegenerative DiseasesJanuary 30, 2024 | finance.yahoo.comVaxxinity Announces Research Collaboration on Active Immunotherapies for Neurodegenerative Diseases with University of FloridaSee More Headlines Receive VAXX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Vaxxinity and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings3/27/2023Today9/07/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:VAXX CUSIPN/A CIK1851657 Webwww.vaxxinity.com Phone254-244-5739FaxN/AEmployees90Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($0.45) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-56,930,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-192.58% Return on Assets-88.04% Debt Debt-to-Equity Ratio0.99 Current Ratio1.89 Quick Ratio1.89 Sales & Book Value Annual Sales$70,000.00 Price / Sales54.32 Cash FlowN/A Price / Cash FlowN/A Book Value$0.11 per share Price / Book0.27Miscellaneous Outstanding Shares126,748,000Free Float45,553,000Market Cap$3.80 million OptionableNot Optionable Beta3.04 Investing Strategies To Help Grow Your Retirement IncomeNeed to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.Get This Free Report Key ExecutivesMr. Louis Garfield Reese IV (Age 42)Co-Founder & Executive Chairman of the Board Comp: $275.57kMs. Mei Mei Hu J.D. (Age 41)Co-Founder, President, CEO & Director Comp: $345.14kMs. Sumita Ray J.D. (Age 50)Chief Legal, Compliance & Administrative Officer and Corporate Secretary Comp: $465.56kDr. Jean-Cosme Dodart Ph.D.Chief Scientific OfficerMr. Jon HarrisonChief Government OfficerMr. Mark Joinnides MSEChief of StaffMs. Amy B. Fix M.B.A.M.S., R.A.C., Head of RegulatoryMore ExecutivesKey CompetitorsBellerophon TherapeuticsNASDAQ:BLPHPainReformNASDAQ:PRFXTRACON PharmaceuticalsNASDAQ:TCONPeak BioNASDAQ:PKBOChina SXT PharmaceuticalsNASDAQ:SXTCView All CompetitorsInsidersMovers Lab Fund I Lp PrimeSold 25,089 sharesTotal: $41,898.63 ($1.67/share)View All Insider Transactions VAXX Stock Analysis - Frequently Asked Questions How have VAXX shares performed this year? Vaxxinity's stock was trading at $0.85 on January 1st, 2024. Since then, VAXX shares have decreased by 96.5% and is now trading at $0.03. View the best growth stocks for 2024 here. How were Vaxxinity's earnings last quarter? Vaxxinity, Inc. (NASDAQ:VAXX) issued its earnings results on Monday, March, 27th. The company reported ($0.16) earnings per share for the quarter, meeting analysts' consensus estimates of ($0.16). When did Vaxxinity IPO? Vaxxinity (VAXX) raised $90 million in an initial public offering on Thursday, November 11th 2021. The company issued 6,000,000 shares at $14.00-$16.00 per share. How do I buy shares of Vaxxinity? Shares of VAXX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:VAXX) was last updated on 9/7/2024 by MarketBeat.com Staff From Our PartnersPerfect Crypto Buying Opportunity for 50 CentsWhen cryptos take a hit, the mom and pop investors run for the hills. But the top investors keep buying wit...Crypto 101 Media | SponsoredThe solution to fast food’s wage hike crisisShake Shack will be closing six California locations in response to the recent $20/hour minimum wage increase,...Deal Maker | SponsoredPre-IPO| 32,481% Growth: First Disruption to $martphones in 15 Years🤳45M Users | 32,481% Growth Rate Get in on the biggest disruption to smartphones in over a decade. Reg A inv...Mode Mobile | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredSay Goodbye to the US DollarThe warning signs are everywhere… According to experts, the United States Dollar is "as good as doomed." ...Sasco Gold LLC | SponsoredElon Musk’s chilling warning for humanityThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | SponsoredThese 5 stocks could soar after November 4thHow to Trade this Crazy Election Year? Simple – Just Focus on These 5 stocks… Now available – a free report...StockEarnings | SponsoredMan who Predicted Trump 2016 Win: “Prepare for Election Meltdown”Former advisor to the CIA, the Pentagon and the White House Jim Rickards went on multiple TV news programs… ...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Vaxxinity, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Vaxxinity With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.